APO Research
Talk to an analyst

APO RESEARCH · REPORT

Trivalent Flu Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Trivalent Flu Vaccine Industry Growth and Trends Forecast to 2032

20 December 202592 pages

Choose your research edition.

Industry ResearchTrivalent Flu Vaccine Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Trivalent Flu Vaccine Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Trivalent Flu Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Trivalent Flu Vaccine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Trivalent Flu Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Trivalent Flu Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Trivalent Flu Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Trivalent Flu Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Trivalent Flu Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Trivalent Flu Vaccine include Abbott, GlaxoSmithKline, AstraZeneca, Serum Institute of India, Sanofi Pasteur and CSL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Trivalent Flu Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Trivalent Flu Vaccine market size, estimates, and forecasts are presented in terms of sales volume (k doses) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Trivalent Flu Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Trivalent Flu Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Trivalent Flu Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Trivalent Flu Vaccine Market by Company

Abbott

GlaxoSmithKline

AstraZeneca

Serum Institute of India

Sanofi Pasteur

CSL

Trivalent Flu Vaccine Segment by Type

Intramuscular Injection

Nasal Spray

Intradermal Shot

Trivalent Flu Vaccine Segment by Application

Public Health Agency

Hospital

Clinic

Other

Trivalent Flu Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Trivalent Flu Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Trivalent Flu Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Trivalent Flu Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Trivalent Flu Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Trivalent Flu Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Intramuscular Injection Table 2. Major Company of Nasal Spray Table 3. Major Company of Intradermal Shot Table 4. Global Trivalent Flu Vaccine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Trivalent Flu Vaccine Sales by Type (2021-2026) & (k doses) Table 6. Global Trivalent Flu Vaccine Sales Market Share in Volume by Type (2021-2026) Table 7. Global Trivalent Flu Vaccine Sales by Type (2021-2026) & (US$ Million) Table 8. Global Trivalent Flu Vaccine Sales Market Share in Value by Type (2021-2026) Table 9. Global Trivalent Flu Vaccine Price by Type (2021-2026) & (US$/dose) Table 10. Global Trivalent Flu Vaccine Sales by Type (2027-2032) & (k doses) Table 11. Global Trivalent Flu Vaccine Sales Market Share in Volume by Type (2027-2032) Table 12. Global Trivalent Flu Vaccine Sales by Type (2027-2032) & (US$ Million) Table 13. Global Trivalent Flu Vaccine Sales Market Share in Value by Type (2027-2032) Table 14. Global Trivalent Flu Vaccine Price by Type (2027-2032) & (US$/dose) Table 15. North America Trivalent Flu Vaccine Sales by Type (2021-2026) & (k doses) Table 16. North America Trivalent Flu Vaccine Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Trivalent Flu Vaccine Sales by Type (2021-2026) & (k doses) Table 18. Europe Trivalent Flu Vaccine Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Trivalent Flu Vaccine Sales by Type (2021-2026) & (k doses) Table 20. Asia-Pacific Trivalent Flu Vaccine Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Trivalent Flu Vaccine Sales by Type (2021-2026) & (k doses) Table 22. Latin America Trivalent Flu Vaccine Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Trivalent Flu Vaccine Sales by Type (2021-2026) & (k doses) Table 24. Middle East and Africa Trivalent Flu Vaccine Sales by Type (2021-2026) & (US$ Million) Table 25. Trivalent Flu Vaccine Industry Trends Table 26. Trivalent Flu Vaccine Industry Drivers Table 27. Trivalent Flu Vaccine Industry Opportunities and Challenges Table 28. Trivalent Flu Vaccine Industry Restraints Table 29. Global Trivalent Flu Vaccine Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Trivalent Flu Vaccine Revenue Market Share by Company (2021-2026) Table 31. Global Trivalent Flu Vaccine Sales by Company (2021-2026) & (k doses) Table 32. Global Trivalent Flu Vaccine Sales Share by Company (2021-2026) Table 33. Global Trivalent Flu Vaccine Market Price by Company (2021-2026) & (US$/dose) Table 34. Global Trivalent Flu Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Trivalent Flu Vaccine Major Company Production Sites and Headquarters Table 36. Global Trivalent Flu Vaccine Company, Product Type & Application Table 37. Global Trivalent Flu Vaccine Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Trivalent Flu Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Trivalent Flu Vaccine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Trivalent Flu Vaccine Sales by Region (2021-2026) & (k doses) Table 42. Global Trivalent Flu Vaccine Sales Market Share in Volume by Region (2021-2026) Table 43. Global Trivalent Flu Vaccine Sales by Region (2021-2026) & (US$ Million) Table 44. Global Trivalent Flu Vaccine Sales Market Share in Value by Region (2021-2026) Table 45. Global Trivalent Flu Vaccine Sales (k doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 46. Global Trivalent Flu Vaccine Sales by Region (2027-2032) & (k doses) Table 47. Global Trivalent Flu Vaccine Sales Market Share in Volume by Region (2027-2032) Table 48. Global Trivalent Flu Vaccine Sales by Region (2027-2032) & (US$ Million) Table 49. Global Trivalent Flu Vaccine Sales Market Share in Value by Region (2027-2032) Table 50. Global Trivalent Flu Vaccine Sales (k doses), Value (US$ Million), Price (US$/dose) and Gross Margin (2027-2032) Table 51. Global Trivalent Flu Vaccine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Trivalent Flu Vaccine Sales by Application (2021-2026) & (k doses) Table 53. Global Trivalent Flu Vaccine Sales Market Share in Volume by Application (2021-2026) Table 54. Global Trivalent Flu Vaccine Sales by Application (2021-2026) & (US$ Million) Table 55. Global Trivalent Flu Vaccine Sales Market Share in Value by Application (2021-2026) Table 56. Global Trivalent Flu Vaccine Price by Application (2021-2026) & (US$/dose) Table 57. Global Trivalent Flu Vaccine Sales by Application (2027-2032) & (k doses) Table 58. Global Trivalent Flu Vaccine Sales Market Share in Volume by Application (2027-2032) Table 59. Global Trivalent Flu Vaccine Sales by Application (2027-2032) & (US$ Million) Table 60. Global Trivalent Flu Vaccine Sales Market Share in Value by Application (2027-2032) Table 61. Global Trivalent Flu Vaccine Price by Application (2027-2032) & (US$/dose) Table 62. North America Trivalent Flu Vaccine Sales by Application (2021-2026) & (k doses) Table 63. North America Trivalent Flu Vaccine Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Trivalent Flu Vaccine Sales by Application (2021-2026) & (k doses) Table 65. Europe Trivalent Flu Vaccine Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Trivalent Flu Vaccine Sales by Application (2021-2026) & (k doses) Table 67. Asia-Pacific Trivalent Flu Vaccine Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Trivalent Flu Vaccine Sales by Application (2021-2026) & (k doses) Table 69. Latin America Trivalent Flu Vaccine Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Trivalent Flu Vaccine Sales by Application (2021-2026) & (k doses) Table 71. Middle East and Africa Trivalent Flu Vaccine Sales by Application (2021-2026) & (US$ Million) Table 72. Abbott Company Information Table 73. Abbott Business Overview Table 74. Abbott Trivalent Flu Vaccine Sales (k doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 75. Abbott Trivalent Flu Vaccine Product Portfolio Table 76. Abbott Recent Development Table 77. GlaxoSmithKline Company Information Table 78. GlaxoSmithKline Business Overview Table 79. GlaxoSmithKline Trivalent Flu Vaccine Sales (k doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 80. GlaxoSmithKline Trivalent Flu Vaccine Product Portfolio Table 81. GlaxoSmithKline Recent Development Table 82. AstraZeneca Company Information Table 83. AstraZeneca Business Overview Table 84. AstraZeneca Trivalent Flu Vaccine Sales (k doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 85. AstraZeneca Trivalent Flu Vaccine Product Portfolio Table 86. AstraZeneca Recent Development Table 87. Serum Institute of India Company Information Table 88. Serum Institute of India Business Overview Table 89. Serum Institute of India Trivalent Flu Vaccine Sales (k doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 90. Serum Institute of India Trivalent Flu Vaccine Product Portfolio Table 91. Serum Institute of India Recent Development Table 92. Sanofi Pasteur Company Information Table 93. Sanofi Pasteur Business Overview Table 94. Sanofi Pasteur Trivalent Flu Vaccine Sales (k doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 95. Sanofi Pasteur Trivalent Flu Vaccine Product Portfolio Table 96. Sanofi Pasteur Recent Development Table 97. CSL Company Information Table 98. CSL Business Overview Table 99. CSL Trivalent Flu Vaccine Sales (k doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 100. CSL Trivalent Flu Vaccine Product Portfolio Table 101. CSL Recent Development Table 102. North America Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 103. North America Trivalent Flu Vaccine Sales by Country (2021-2026) & (k doses) Table 104. North America Trivalent Flu Vaccine Sales Market Share by Country (2021-2026) Table 105. North America Trivalent Flu Vaccine Sales Forecast by Country (2027-2032) & (k doses) Table 106. North America Trivalent Flu Vaccine Sales Market Share Forecast by Country (2027-2032) Table 107. North America Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 108. North America Trivalent Flu Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 109. North America Trivalent Flu Vaccine Market Share by Country (2021-2026) Table 110. North America Trivalent Flu Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 111. North America Trivalent Flu Vaccine Market Share Forecast by Country (2027-2032) Table 112. Europe Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 113. Europe Trivalent Flu Vaccine Sales by Country (2021-2026) & (k doses) Table 114. Europe Trivalent Flu Vaccine Sales Market Share by Country (2021-2026) Table 115. Europe Trivalent Flu Vaccine Sales Forecast by Country (2027-2032) & (k doses) Table 116. Europe Trivalent Flu Vaccine Sales Market Share Forecast by Country (2027-2032) Table 117. Europe Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 118. Europe Trivalent Flu Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 119. Europe Trivalent Flu Vaccine Market Share by Country (2021-2026) Table 120. Europe Trivalent Flu Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 121. Europe Trivalent Flu Vaccine Market Share Forecast by Country (2027-2032) Table 122. Asia-Pacific Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 123. Asia-Pacific Trivalent Flu Vaccine Sales by Country (2021-2026) & (k doses) Table 124. Asia-Pacific Trivalent Flu Vaccine Sales Market Share by Country (2021-2026) Table 125. Asia-Pacific Trivalent Flu Vaccine Sales Forecast by Country (2027-2032) & (k doses) Table 126. Asia-Pacific Trivalent Flu Vaccine Sales Market Share Forecast by Country (2027-2032) Table 127. Asia-Pacific Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. Asia-Pacific Trivalent Flu Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 129. Asia-Pacific Trivalent Flu Vaccine Market Share by Country (2021-2026) Table 130. Asia-Pacific Trivalent Flu Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. Asia-Pacific Trivalent Flu Vaccine Market Share Forecast by Country (2027-2032) Table 132. Latin America Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 133. Latin America Trivalent Flu Vaccine Sales by Country (2021-2026) & (k doses) Table 134. Latin America Trivalent Flu Vaccine Sales Market Share by Country (2021-2026) Table 135. Latin America Trivalent Flu Vaccine Sales Forecast by Country (2027-2032) & (k doses) Table 136. Latin America Trivalent Flu Vaccine Sales Market Share Forecast by Country (2027-2032) Table 137. Latin America Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Latin America Trivalent Flu Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 139. Latin America Trivalent Flu Vaccine Market Share by Country (2021-2026) Table 140. Latin America Trivalent Flu Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Latin America Trivalent Flu Vaccine Market Share Forecast by Country (2027-2032) Table 142. Middle East and Africa Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 143. Middle East and Africa Trivalent Flu Vaccine Sales by Country (2021-2026) & (k doses) Table 144. Middle East and Africa Trivalent Flu Vaccine Sales Market Share by Country (2021-2026) Table 145. Middle East and Africa Trivalent Flu Vaccine Sales Forecast by Country (2027-2032) & (k doses) Table 146. Middle East and Africa Trivalent Flu Vaccine Sales Market Share Forecast by Country (2027-2032) Table 147. Middle East and Africa Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Middle East and Africa Trivalent Flu Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 149. Middle East and Africa Trivalent Flu Vaccine Market Share by Country (2021-2026) Table 150. Middle East and Africa Trivalent Flu Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Middle East and Africa Trivalent Flu Vaccine Market Share Forecast by Country (2027-2032) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Trivalent Flu Vaccine Distributors List Table 155. Trivalent Flu Vaccine Customers List Table 156. Research Programs/Design for This Report Table 157. Authors List of This Report Table 158. Secondary Sources Table 159. Primary Sources List of Figures Figure 1. Trivalent Flu Vaccine Image Figure 2. Global Trivalent Flu Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Trivalent Flu Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Trivalent Flu Vaccine Sales (2021-2032) & (k doses) Figure 5. Intramuscular Injection Image Figure 6. Global Intramuscular Injection Sales YoY Growth (2021-2032) & (k doses) Figure 7. Nasal Spray Image Figure 8. Global Nasal Spray Sales YoY Growth (2021-2032) & (k doses) Figure 9. Intradermal Shot Image Figure 10. Global Intradermal Shot Sales YoY Growth (2021-2032) & (k doses) Figure 11. Global Trivalent Flu Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Trivalent Flu Vaccine Market Share by Type 2025 VS 2032 Figure 13. North America Trivalent Flu Vaccine Sales Market Share in Volume by Type in 2025 Figure 14. North America Trivalent Flu Vaccine Sales Market Share in Value by Type in 2025 Figure 15. Europe Trivalent Flu Vaccine Sales Market Share in Volume by Type in 2025 Figure 16. Europe Trivalent Flu Vaccine Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Trivalent Flu Vaccine Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Trivalent Flu Vaccine Sales Market Share in Value by Type in 2025 Figure 19. Latin America Trivalent Flu Vaccine Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Trivalent Flu Vaccine Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Trivalent Flu Vaccine Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Trivalent Flu Vaccine Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Trivalent Flu Vaccine Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Public Health Agency Image Figure 26. Global Public Health Agency Sales YoY Growth (2021-2032) & (k doses) Figure 27. Hospital Image Figure 28. Global Hospital Sales YoY Growth (2021-2032) & (k doses) Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (k doses) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (k doses) Figure 33. Global Trivalent Flu Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Trivalent Flu Vaccine Market Share by Application 2025 VS 2032 Figure 35. North America Trivalent Flu Vaccine Sales Market Share in Volume by Application in 2025 Figure 36. North America Trivalent Flu Vaccine Sales Market Share in Value by Application in 2025 Figure 37. Europe Trivalent Flu Vaccine Sales Market Share in Volume by Application in 2025 Figure 38. Europe Trivalent Flu Vaccine Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Trivalent Flu Vaccine Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Trivalent Flu Vaccine Sales Market Share in Value by Application in 2025 Figure 41. Latin America Trivalent Flu Vaccine Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Trivalent Flu Vaccine Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Trivalent Flu Vaccine Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Trivalent Flu Vaccine Sales Market Share in Value by Application in 2025 Figure 45. North America Trivalent Flu Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 46. North America Trivalent Flu Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Trivalent Flu Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Trivalent Flu Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Trivalent Flu Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 50. Europe Trivalent Flu Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Trivalent Flu Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Trivalent Flu Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Trivalent Flu Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 54. Asia-Pacific Trivalent Flu Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Trivalent Flu Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Trivalent Flu Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Trivalent Flu Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 58. Latin America Trivalent Flu Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Trivalent Flu Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Trivalent Flu Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Trivalent Flu Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 62. Middle East and Africa Trivalent Flu Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Trivalent Flu Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Trivalent Flu Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Trivalent Flu Vaccine Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Trivalent Flu Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Intramuscular Injection
  • Nasal Spray
  • Intradermal Shot
Applications
  • Public Health Agency
  • Hospital
  • Clinic
  • Other
Companies covered
  • Abbott
  • GlaxoSmithKline
  • AstraZeneca
  • Serum Institute of India
  • Sanofi Pasteur
  • CSL

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Trivalent Flu Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Trivalent Flu Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Trivalent Flu Vaccine Market by Type
  6. 1.3.1 Intramuscular Injection
  7. 1.3.2 Nasal Spray
  8. 1.3.3 Intradermal Shot
  9. 1.4 Global Trivalent Flu Vaccine Market Size by Type
  10. 1.4.1 Global Trivalent Flu Vaccine Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Trivalent Flu Vaccine Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Trivalent Flu Vaccine Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Trivalent Flu Vaccine Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Trivalent Flu Vaccine Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Trivalent Flu Vaccine Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Trivalent Flu Vaccine Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Trivalent Flu Vaccine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Trivalent Flu Vaccine Industry Trends
  2. 2.2 Trivalent Flu Vaccine Industry Drivers
  3. 2.3 Trivalent Flu Vaccine Industry Opportunities and Challenges
  4. 2.4 Trivalent Flu Vaccine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Trivalent Flu Vaccine Revenue (2021-2026)
  2. 3.2 Global Top Players by Trivalent Flu Vaccine Sales (2021-2026)
  3. 3.3 Global Top Players by Trivalent Flu Vaccine Price (2021-2026)
  4. 3.4 Global Trivalent Flu Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Trivalent Flu Vaccine Major Company Production Sites & Headquarters
  6. 3.6 Global Trivalent Flu Vaccine Company, Product Type & Application
  7. 3.7 Global Trivalent Flu Vaccine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Trivalent Flu Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Trivalent Flu Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Trivalent Flu Vaccine Tier 1, Tier 2, and Tier 3
4 Trivalent Flu Vaccine Regional Status and Outlook
  1. 4.1 Global Trivalent Flu Vaccine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Trivalent Flu Vaccine Historic Market Size by Region
  3. 4.2.1 Global Trivalent Flu Vaccine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Trivalent Flu Vaccine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Trivalent Flu Vaccine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Trivalent Flu Vaccine Forecasted Market Size by Region
  7. 4.3.1 Global Trivalent Flu Vaccine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Trivalent Flu Vaccine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Trivalent Flu Vaccine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Trivalent Flu Vaccine by Application
  1. 5.1 Trivalent Flu Vaccine Market by Application
  2. 5.1.1 Public Health Agency
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Other
  6. 5.2 Global Trivalent Flu Vaccine Market Size by Application
  7. 5.2.1 Global Trivalent Flu Vaccine Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Trivalent Flu Vaccine Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Trivalent Flu Vaccine Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Trivalent Flu Vaccine Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Trivalent Flu Vaccine Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Trivalent Flu Vaccine Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Trivalent Flu Vaccine Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Trivalent Flu Vaccine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Abbott
  2. 6.1.1 Abbott Company Information
  3. 6.1.2 Abbott Business Overview
  4. 6.1.3 Abbott Trivalent Flu Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Abbott Trivalent Flu Vaccine Product Portfolio
  6. 6.1.5 Abbott Recent Developments
  7. 6.2 GlaxoSmithKline
  8. 6.2.1 GlaxoSmithKline Company Information
  9. 6.2.2 GlaxoSmithKline Business Overview
  10. 6.2.3 GlaxoSmithKline Trivalent Flu Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 GlaxoSmithKline Trivalent Flu Vaccine Product Portfolio
  12. 6.2.5 GlaxoSmithKline Recent Developments
  13. 6.3 AstraZeneca
  14. 6.3.1 AstraZeneca Company Information
  15. 6.3.2 AstraZeneca Business Overview
  16. 6.3.3 AstraZeneca Trivalent Flu Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 AstraZeneca Trivalent Flu Vaccine Product Portfolio
  18. 6.3.5 AstraZeneca Recent Developments
  19. 6.4 Serum Institute of India
  20. 6.4.1 Serum Institute of India Company Information
  21. 6.4.2 Serum Institute of India Business Overview
  22. 6.4.3 Serum Institute of India Trivalent Flu Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Serum Institute of India Trivalent Flu Vaccine Product Portfolio
  24. 6.4.5 Serum Institute of India Recent Developments
  25. 6.5 Sanofi Pasteur
  26. 6.5.1 Sanofi Pasteur Company Information
  27. 6.5.2 Sanofi Pasteur Business Overview
  28. 6.5.3 Sanofi Pasteur Trivalent Flu Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sanofi Pasteur Trivalent Flu Vaccine Product Portfolio
  30. 6.5.5 Sanofi Pasteur Recent Developments
  31. 6.6 CSL
  32. 6.6.1 CSL Company Information
  33. 6.6.2 CSL Business Overview
  34. 6.6.3 CSL Trivalent Flu Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 CSL Trivalent Flu Vaccine Product Portfolio
  36. 6.6.5 CSL Recent Developments
7 North America by Country
  1. 7.1 North America Trivalent Flu Vaccine Sales by Country
  2. 7.1.1 North America Trivalent Flu Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Trivalent Flu Vaccine Sales by Country (2021-2026)
  4. 7.1.3 North America Trivalent Flu Vaccine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Trivalent Flu Vaccine Market Size by Country
  6. 7.2.1 North America Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Trivalent Flu Vaccine Market Size by Country (2021-2026)
  8. 7.2.3 North America Trivalent Flu Vaccine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Trivalent Flu Vaccine Sales by Country
  2. 8.1.1 Europe Trivalent Flu Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Trivalent Flu Vaccine Sales by Country (2021-2026)
  4. 8.1.3 Europe Trivalent Flu Vaccine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Trivalent Flu Vaccine Market Size by Country
  6. 8.2.1 Europe Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Trivalent Flu Vaccine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Trivalent Flu Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Trivalent Flu Vaccine Sales by Country
  2. 9.1.1 Asia-Pacific Trivalent Flu Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Trivalent Flu Vaccine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Trivalent Flu Vaccine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Trivalent Flu Vaccine Market Size by Country
  6. 9.2.1 Asia-Pacific Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Trivalent Flu Vaccine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Trivalent Flu Vaccine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Trivalent Flu Vaccine Sales by Country
  2. 10.1.1 South America Trivalent Flu Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Trivalent Flu Vaccine Sales by Country (2021-2026)
  4. 10.1.3 South America Trivalent Flu Vaccine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Trivalent Flu Vaccine Market Size by Country
  6. 10.2.1 South America Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Trivalent Flu Vaccine Market Size by Country (2021-2026)
  8. 10.2.3 South America Trivalent Flu Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Trivalent Flu Vaccine Sales by Country
  2. 11.1.1 Middle East and Africa Trivalent Flu Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Trivalent Flu Vaccine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Trivalent Flu Vaccine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Trivalent Flu Vaccine Market Size by Country
  6. 11.2.1 Middle East and Africa Trivalent Flu Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Trivalent Flu Vaccine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Trivalent Flu Vaccine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Trivalent Flu Vaccine Value Chain Analysis
  2. 12.1.1 Trivalent Flu Vaccine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Trivalent Flu Vaccine Production Mode & Process
  7. 12.2 Trivalent Flu Vaccine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Trivalent Flu Vaccine Distributors
  10. 12.2.3 Trivalent Flu Vaccine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst